Carbapenem-Based Antibiotics Market Research Report and Outlook by 2028

The market for carbapenem-based antibiotics is anticipated to grow significantly, with projections indicating it will reach approximately US$ 5,346.62 million by 2028, up from US$ 3,964.57 million in 2021. This growth represents a compound annual growth rate (CAGR) of 4.4% from 2021 to 2028.

One of the key drivers of this market is the increasing popularity of generic antibiotics, which are favored for their accessibility and lower costs. The expiration of patents for several carbapenem-based antibiotics has opened the door for generic manufacturers to introduce their more affordable alternatives. These companies are focused on expanding the availability of these essential medications. Additionally, the ongoing shortage of antibiotics for treating bacterial infections is a significant factor contributing to the market's expansion. The rise in production of generic carbapenem antibiotics has improved drug availability, particularly in low- and middle-income nations.

Among the generic carbapenem drugs currently available are ertapenem (Invanz), imipenem/cilastatin (Primaxin IM), doripenem (Doribax), and meropenem (Merrem). The increasing number of generic manufacturers is further propelling the production of these antibiotics. Numerous companies in Asia are actively involved in the development of active pharmaceutical ingredients (APIs) necessary for the production of generic carbapenem antibiotics. For instance, in June 2021, JW Pharmaceutical, a South Korean firm, announced the completion of its API production for Ertapenem injection, which was subsequently shipped to the United States. The company aims to penetrate the global carbapenem antibiotic market in the near future and has successfully developed its own technology in Korea for producing Doripenem. Furthermore, JW Pharmaceutical plans to enhance the sales of both APIs and finished products for Imipenem and Meropenem, targeting exports to over 40 countries, including China and Japan. This trend of increasing generic drug production is a significant factor driving the growth of the global carbapenem-based antibiotics market.

The carbapenem-based antibiotics market is categorized by type into meropenem, doripenem, imipenem, tebipenem, and others. In 2021, the "others" segment captured the largest market share and is projected to experience the highest CAGR during the forecast period, driven by ongoing advancements in carbapenem antibiotic development.

When segmented by indication, the market includes categories such as bacterial meningitis, acute pelvic infections, respiratory tract infections, intra-abdominal infections, urinary tract infections, and others. Again, the "others" segment held the largest share in 2021 and is expected to register the highest growth rate in the coming years.

In terms of distribution channels, the market is divided into retail pharmacies, online pharmacies, and hospital pharmacies. The hospital pharmacies segment dominated the market in 2021 and is projected to maintain the highest growth rate throughout the forecast period.

Geographically, the carbapenem-based antibiotics market is segmented into North America, Europe, Asia Pacific, Middle East and Africa, and South and Central America. North America currently holds the largest share of the global market and is expected to continue its strong presence in the years ahead. This region is likely to see steady growth due to factors such as the increasing adoption of carbapenem antibiotics, a high rate of antibiotic prescriptions, and advancements in research and development that lead to the introduction of new medications. Conversely, the Asia Pacific region is projected to experience the fastest growth in the near future. The carbapenem-based antibiotics market in countries like India and China is expected to expand rapidly, driven by a large population, a growing focus from market players on developing innovative and affordable products, and a significant presence of manufacturers producing generic drugs for global export.

In preparing the report on the global carbapenem-based antibiotics market, various primary and secondary sources were consulted, including the World Health Organization (WHO), Food and Drug Administration (FDA), Saudi Clinical Trial Registry, National Institute for Health, Ministry of Health and Prevention, and Centers for Disease Control and Prevention (CDC).